WCMNY
BMRN icon

Westchester Capital Management (New York)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Westchester Capital Management (New York)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,700
Closed -$3.02M – 193
2024
Q2 		$3.02M Hold
36,700
– – 0.11% 101
2024
Q1 		$3.21M Sell
36,700
-81,700
-69% -$7.31M 0.12% 113
2023
Q4 		$11.4M Buy
+118,400
New +$10.5M 0.4% 44

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Westchester Capital Management (New York)'s BMRN Position: Q3 2024 in Review

Westchester Capital Management (New York) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 36,700 shares — an estimated $3.02M sold.

Westchester Capital Management (New York) first reported a position in BMRN in Q4 2023 and held it in 3 quarters. The position peaked at $11.4M in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Westchester Capital Management (New York) reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 36,700 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $3.02M.
  • Westchester Capital Management (New York) first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Westchester Capital Management (New York)'s BioMarin Pharmaceuticals position peaked at $11.4M in Q4 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.